Fielding Johnson, MD
Pulmonary Disease · East Hartford, CTNPI 1346336237
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 1,072 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Among pulmonary disease clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,072 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$5K
- AstraZeneca$3K
- Amgen$2K
- AbbVie$2K
- Boehringer Ingelheim$2K
- Mallinckrodt Hospital Products Inc.$2K
- plus $15K from 54 others
What the payments were for
- Food & beverage$30,23199%
- Education$3721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$1,358
- CAPLYTA$983
- TRELEGY ELLIPTA$730
- ACTHAR$614
- Repatha$461
- DUPIXENT$376
- BREZTRI$372
- VRAYLAR$371
- AIRSUPRA$369
- ELIQUIS$367
- UPTRAVI$366
- OPSUMIT$366
- INGREZZA$249
- UBRELVY$246
- INVOKANA$217
- CHARTIS CATHETER$160
- ZEPHYR DELIVERY CATHETER$160
- ZEPHYR ENDOBRONCHIAL VALVE$160
- PULMONX CHARTIS TABLET CONSOLE$160
- Morphabond ER$152
How this compares
$30,602 in reported general payments places this provider in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 184 | $210,266 |
| IngrezzaValbenazine Tosylate | 49 | $181,432 |
| EliquisApixaban | 158 | $56,208 |
| JardianceEmpagliflozin | 145 | $55,920 |
| TrulicityDulaglutide | 55 | $44,240 |
| Breo ElliptaFluticasone/Vilanterol | 63 | $38,957 |
| OxycontinOxycodone Hcl | 38 | $38,623 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $31,662 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $26,402 |
| XareltoRivaroxaban | 68 | $23,134 |
| TradjentaLinagliptin | 77 | $20,237 |
| JanuviaSitagliptin Phosphate | 55 | $19,551 |
| Divalproex Sodium | 161 | $16,242 |
| FarxigaDapagliflozin Propanediol | 40 | $11,921 |
| JanumetSitagliptin Phos/Metformin Hcl | 41 | $11,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $4,833 | $275,626279 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $280 | $181,43249 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $1,638 | $82,613233 claims |
| PfizerEliquis | $399 | $56,208158 claims |
| Lilly USA, LLCTrulicity, Humalog | $1,282 | $50,781142 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $2,737 | $50,66974 claims |
| MerckJanuvia, Janumet | $103 | $31,26496 claims |
| Johnson & JohnsonXarelto | $516 | $23,13468 claims |
| Sanofi-aventis U.S. LLCLantus | $791 | $6,27987 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 pulmonary disease providers in Connecticut.
Other pulmonary disease in East Hartford
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.